SecBot SecBot
6-K ·Filed Aug 27, 2026

FMS

Fresenius Medical Care AG
BULLISH
Impact 5/10
Horizonweeks Processed2mo ago SEC0001104659-26-102053
Notable filing: 6-K
Actionable Insight ▲ Bullish

This clinical publication strengthens the evidence base for high-volume HDF, which could accelerate U.S. adoption and reimbursement decisions. Monitor for any subsequent guidance updates, U.S. payer coverage announcements, or competitive responses from DaVita/other dialysis providers. The stock may see modest positive momentum as the market prices in improved long-term growth prospects for HVHDF.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$23.27
T+0 close · Aug 27, 2026 · via day close
Latest settled
−3.95%
T+20 · $22.35 · next T+60 in 3d
Vs SPY
−3.45%
α at T+20
Latest observation
−5.81%
T+56 · FF3 residual α
  1. T+0 · Aug 27 $23.27entry
  2. T+1 · 3mo ago −0.73%α −0.50% · $23.10
  3. T+5 · 3mo ago −3.44%α −3.71% · $22.47
  4. T+20 · 8w ago −3.95%α −3.45% · $22.35
  5. T+56 · todayOpen
  6. T+60 · in 3d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fresenius Medical Care announced the publication of a multinational real-world evidence study in the Journal of the American Society of Nephrology, reporting that hemodiafiltration (HDF) was associated with a 28% lower relative risk of all-cause mortality compared with conventional high-flux hemodialysis. The study analyzed nearly 20,000 patients across eight European countries, with the strongest benefit (33% lower relative risk) seen at convection volumes above 23 liters per session. This is a clinical evidence milestone that supports the company's strategy to expand high-volume HDF access, particularly in the U.S., but does not provide any financial data or guidance.

Key Facts

  • Study published in JASN found HDF associated with 28% lower relative risk of all-cause mortality vs. high-flux hemodialysis
  • Nearly 20,000 patients across eight European countries analyzed using target trial emulation
  • Patients receiving convection volumes above 23L/session had 33% lower relative risk of death
  • Fresenius Medical Care is expanding access to high-volume HDF in the United States
  • Company references its BEACON-US research initiative to generate U.S.-specific real-world evidence

Financial Impact

No financial figures provided in the filing; the study is a clinical evidence milestone that could support future reimbursement and adoption of HVHDF, potentially driving revenue growth over time

Risk Factors

  • Observational study design does not establish causality; association between higher convection volumes and lower mortality may reflect patient stability rather than causal dose-response
  • No financial data or guidance provided in this filing; commercial impact depends on future reimbursement and adoption rates
  • Expanding HVHDF access in the U.S. may require significant capital investment and face regulatory hurdles

Market Snapshot

Exchange
OTC
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
24% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-102053
Document: 0001104659-26-102053-index-headers.html0001104659-26-102053
Document: 0001104659-26-102053-index.html0001104659-26-102053
Document: 0001104659-26-102053.txt0001104659-26-102053

Track record

16 reports on FMS

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.43% at T+60 after the Apr 7, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13D/A Bearish 5/10 Entry $22.03 Now $21.86 +0.77% settles Nov 20
  2. Nov 9, 20267d ago 6-K Neutral 2/10 Entry $22.95 to $21.86 Now $21.86 −4.75% ▼ −4.75% −3.06% vs SPY
  3. Nov 3, 202613d ago 6-K Bearish 6/10 No price data
  4. Nov 3, 202613d ago 6-K Bearish 5/10 Entry $21.73 to $22.74 Now $21.86 −0.60% ▼ −4.65% −5.24% vs SPY
  5. Oct 30, 202618d ago Court Ruling Neutral 4/10 Entry $22.61 to $22.95 Now $21.86 −3.32% ▲ +1.50% +1.43% vs SPY
  6. Oct 7, 20265w ago 6-K Neutral 3/10 Entry $20.69 to $21.54 Now $21.86 +5.65% ▲ +4.11% +5.09% vs SPY
  7. Sep 25, 20267w ago 6-K Bearish 5/10 Entry $22.69 to $22.25 Now $21.86 +3.66% ▲ +1.94% +1.72% vs SPY
  8. Sep 1, 202611w ago Court Ruling Neutral 1/10 Entry $22.65 to $22.23 Now $21.86 −3.49% ▼ −1.85% −0.90% vs SPY
  9. Aug 31, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
  10. Aug 31, 202611w ago Court Ruling Neutral 4/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 27, 2026